Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.79 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.79 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16573726 | 0.90 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6669792 | 0.87 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6669408 | 0.84 | MAPK14 (0.76) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6668555 | 0.82 | MAPK14 (0.80) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6669033 | 0.79 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6869200 | 0.78 | MAPK14 (0.83) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6672113 | 0.77 | MAPK14 (0.78) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6667322 | 0.76 | MAPK14 (0.66) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6667002 | 0.76 | MAPK14 (0.81) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6696682 | 0.76 | MAPK14 (0.78) | MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099651-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-22 | — | — | US | disclosed |
| EP-2086641-A2 | EGFR KINASE INHIBITOR COMBINATIONS FOR THE TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | Boehringer Ingelheim International GmbH (DE) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008049842-A2 | EGFR KINASE INHIBITOR COMBINATIONS FOR THE TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099651-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | BDKRB2, GRK5, PRKCH | MAPK14 71/4885MAPK13 106/4885MAPK12 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.